BioLineRx Files Routine 6-K Foreign Issuer Report on March 26, 2026

TL;DR

**BioLineRx filed a standard 6-K, no major news here.**

AI Summary

BioLineRx Ltd. filed a 6-K report on March 26, 2026, indicating a routine foreign issuer report. This filing, with accession number 0001178913-26-001738, includes several exhibits and graphics, but does not disclose any specific new financial or operational information. For investors, this particular 6-K filing is a standard procedural update and doesn't contain news that would immediately impact the stock price, as it lacks details on new drug developments, financial results, or strategic changes.

Why It Matters

This filing is a standard procedural update for foreign issuers and does not contain new material information that would typically move the stock price. It's important for investors to distinguish routine filings from those containing significant news.

Risk Assessment

Risk Level: low — This 6-K filing is a routine report and does not introduce new risks or significant information that would alter the company's risk profile.

Analyst Insight

Smart investors should note that this 6-K is a standard procedural filing and does not contain new material information. No immediate action is warranted based solely on this report; focus should remain on other filings or news that disclose financial results, clinical trial updates, or strategic developments.

Key Numbers

• 2026-03-26 — Filing Date (The date the 6-K report was filed by BioLineRx Ltd.)
• 5 — Number of Documents (The total number of documents included in the 6-K submission.)

Key Players & Entities

• BioLineRx Ltd. (company) — the filer of the 6-K report
• 0001498403 (company) — CIK of BioLineRx Ltd.
• 0001178913-26-001738 (dollar_amount) — SEC Accession No. for the filing

Forward-Looking Statements

• BioLineRx Ltd. will continue to file routine 6-K reports as required by SEC regulations for foreign issuers. (BioLineRx Ltd.) — high confidence, target: 2027-03-26

FAQ

Filing Documents

• zk2634945.htm (6-K) — 8KB
• exhibit_1.htm (EX-99.1) — 15KB
• image1.jpg (GRAPHIC) — 32KB
• image2.jpg (GRAPHIC) — 32KB
• image00003.jpg (GRAPHIC) — 27KB
• 0001178913-26-001738.txt ( ) — 152KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On March 26, 2026, the registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K. The first paragraph of the press release attached to this Form 6-K as Exhibit 1 is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: March 26, 2026

View Full Filing

View this 6-K filing on SEC EDGAR